Literature DB >> 25030802

Effects of quetiapine treatment on cocaine self-administration and behavioral indices of sleep in adult rhesus monkeys.

Robert E Brutcher1, Michael A Nader.   

Abstract

RATIONALE: Clinical literature suggests a link between substance abuse and sleep disturbances. Quetiapine, an atypical antipsychotic, has shown efficacy in treating sleep disturbances, with clinical studies showing promise for quetiapine as a treatment for cocaine abuse.
OBJECTIVE: The goal of this study was to examine the effects of quetiapine on cocaine self-administration and behavioral indices of sleep in monkeys.
METHODS: Seven adult male rhesus monkeys, fitted with Actical® activity monitors, were trained to respond under a choice paradigm of food (1.0-g pellets) and cocaine (0.003-0.3 mg/kg per injection) presentation. First, monkeys received acute pretreatment (45 min) with quetiapine (25-75 mg, p.o.) prior to choice sessions; three cocaine doses were studied in combination with quetiapine. Next, the effect of chronic (14-16 days) quetiapine treatment (25-250 mg, p.o., BID) was examined in combination with the lowest preferred cocaine dose (≥80 % cocaine choice). Behavioral indices of sleep, based on activity measures obtained during lights-out, were recorded throughout the study.
RESULTS: Acute quetiapine decreased cocaine choice in four of the seven monkeys. Chronic quetiapine treatment resulted in initial decreases in cocaine choice, but tolerance developed to these effects. Acute doses of quetiapine did not improve sleep efficiency the following night nor did chronic quetiapine. The first night after discontinuing quetiapine treatment resulted in significant decreases in sleep efficiency and increases in nighttime activity.
CONCLUSIONS: These findings do not offer support for the use of quetiapine as a monotherapy for treatment of cocaine abuse nor as an adjunct therapy to treat sleep disturbances associated with stimulant abuse.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25030802      PMCID: PMC4297597          DOI: 10.1007/s00213-014-3672-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  65 in total

Review 1.  The new and evolving pharmacotherapy of schizophrenia.

Authors:  Robin Emsley; Piet Oosthuizen
Journal:  Psychiatr Clin North Am       Date:  2003-03

2.  PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys.

Authors:  Michael A Nader; Drake Morgan; H Donald Gage; Susan H Nader; Tonya L Calhoun; Nancy Buchheimer; Richard Ehrenkaufer; Robert H Mach
Journal:  Nat Neurosci       Date:  2006-07-09       Impact factor: 24.884

3.  Potential benefits of quetiapine in the treatment of substance dependence disorders.

Authors:  S Pirzada Sattar; Subhash C Bhatia; Frederick Petty
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

Review 4.  The role of actigraphy in sleep medicine.

Authors:  Avi Sadeh; Christine Acebo
Journal:  Sleep Med Rev       Date:  2002-04       Impact factor: 11.609

5.  Quetiapine for the treatment of cocaine dependence: an open-label trial.

Authors:  Annette Kennedy; Amanda Ernst Wood; Andrew J Saxon; Carol Malte; Megan Harvey; Jennifer Jurik; Nael Kilzieh; Cassin Lofgreen; Andre Tapp
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

6.  The relationship between cocaine self-administration and actigraphy-based measures of sleep in adult rhesus monkeys.

Authors:  Robert E Brutcher; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2013-04-21       Impact factor: 4.530

7.  Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Rita Z Goldstein
Journal:  Neurobiol Learn Mem       Date:  2002-11       Impact factor: 2.877

8.  Sleep-promoting properties of quetiapine in healthy subjects.

Authors:  Stefan Cohrs; Andrea Rodenbeck; Zhenghua Guan; Kathrin Pohlmann; Wolfgang Jordan; Andreas Meier; Eckart Rüther
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

9.  Sleep architecture, cocaine and visual learning.

Authors:  Peter T Morgan; Edward F Pace-Schott; Zakir H Sahul; Vladimir Coric; Robert Stickgold; Robert T Malison
Journal:  Addiction       Date:  2008-08       Impact factor: 6.526

10.  Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Adv Pharmacol Sci       Date:  2012-11-28
View more
  6 in total

1.  Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.

Authors:  Matthew L Banks; Blake A Hutsell; Kathryn L Schwienteck; S Stevens Negus
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

Review 2.  Cocaine choice procedures in animals, humans, and treatment-seekers: Can we bridge the divide?

Authors:  Scott J Moeller; William W Stoops
Journal:  Pharmacol Biochem Behav       Date:  2015-09-30       Impact factor: 3.533

3.  Repeated 7-Day Treatment with the 5-HT2C Agonist Lorcaserin or the 5-HT2A Antagonist Pimavanserin Alone or in Combination Fails to Reduce Cocaine vs Food Choice in Male Rhesus Monkeys.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

4.  Evaluation of the Reinforcing Effect of Quetiapine, Alone and in Combination with Cocaine, in Rhesus Monkeys.

Authors:  Robert E Brutcher; Susan H Nader; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2015-12-07       Impact factor: 4.030

Review 5.  Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Authors:  Paul W Czoty; William W Stoops; Craig R Rush
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 6.  A mechanistic overview of approaches for the treatment of psychostimulant dependence.

Authors:  Kathrine Louise Jensen; Søren Brøgger Jensen; Kenneth Lindegaard Madsen
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.